Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo

Study identifier:D1444C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 1-year, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (abbreviated)

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

197

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Mar 2005
Primary Completion Date: -
Study Completion Date: 01 Apr 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria